What is known and objective: Migraine headache is a relatively common, debilitating condition that costs our healthcare system over 78 billion dollars per year. Riboflavin has been advocated as a safe, effective prophylactic therapy for the prevention of migraines. The purpose of this study was to provide a systematic review of the current role of riboflavin in the prophylaxis of migraine headache. 
reduce disability and allow acute treatment to work more effectively. 5, 6 Migraine headache sufferers often experience substantial decreases in work productivity and function. This can result in a decreased quality of life for the patient and high financial burdens on individuals and employers. A conservative estimate of the cost of migraine-related costs in the United States is calculated to be $78 billion dollars per year. [7] [8] [9] Obviously, effective prophylactic therapy for the prevention of migraine headaches could dramatically decrease the cost of health care for these patients and improve their quality of life. The pharmacotherapy of migraine headache prophylaxis begins with the goals of therapy in mind. 10, 11 Drug therapy considerations include the evidence available supporting its efficacy, adverse event profile and the presence of comorbid conditions. 12-14 Consideration should be given to medications with Level A ratings by the American Academy of Neurology (AAN). 6, 15 These drugs include sodium valproate, topiramate, certain beta-blockers issue, antidepressants should be considered and beta-blockers avoided.
Additionally, the available triptan agents are used for the short-term prophylaxis of menstrually related migraine headache. Monotherapy is the preferred first step, starting with low doses and titrating upwards.
An adequate trial should consist of a minimum of 3 months or longer depending on the specific therapy chosen. 6, 10, 11, 15, 16 Brain energy metabolism has been found to be abnormal in migraine headache. 17 Riboflavin catalyses the activity of flavoenzymes in the mitochondrial respiratory chain and improves the clinical and biochemical abnormalities in patients with inborn errors of mitochondrial metabolism. 18, 19 As mitochondrial deficits are suspected in some patients with migraine headache, riboflavin has been evaluated in clinical trials for prophylactic treatment.
The purpose of this study was to provide a systematic review of the efficacy and adverse effects of riboflavin as a prophylactic agent in the treatment of migraine headaches. In addition, we have explored the pharmacogenomic and pharmacokinetic influences that might affect the therapeutic action or adverse drug event profile of riboflavin for this use.
| METHODS
To provide systematic and transparent reporting, we incorporated the 
| RESULTS AND DISCUSSION

| Riboflavin pharmacokinetics
The mechanism of riboflavin absorption in humans is through active transport. 21, 22 Therefore, the process is specific, saturable and competitive, that is structures similar to riboflavin can compete with its absorption. Riboflavin is mainly absorbed in the upper ileum of the human intestine. 23 It has been reported that the absorption of riboflavin follows linear pharmacokinetics with up to 30 mg when given with food, and the absorption half-life was reported to be 1.1 hours.
21
Zempleni and colleagues 24 reported that a maximum of 27 mg of riboflavin per adult was absorbed after a single dose of riboflavin.
The study was conducted using 20 mg, 40 mg and 60 mg doses of the vitamin, and there was no significant difference observed between maximal serum concentrations and area under the curve for the aforementioned doses. Factors, such as the aqueous solubility of the vitamin, the release kinetics of riboflavin from its source (such as food or dosage form), ingestion of vitamin with meal vs without meal, quantity of water consumed and saturable nature of active transport system can affect the bioavailability of the vitamin.
22-26
Riboflavin is rapidly equilibrated between central and peripheral compartments. It first distributes into the central compartment and then enters into the peripheral compartment in the body. 27 The elimination half-life of riboflavin is approximately one hour.
24
A delay in the tissue uptake of the vitamin occurs which is attributed to specific transport proteins required for the vitamin to penetrate through the cell membranes.
25
Riboflavin is primarily excreted unchanged in urine. Other routes of excretion, such as secretion into the breast milk, may also contribute to the overall excretion of the vitamin. 14,18 Elimination of riboflavin in bile has been reported to be negligible (less than one per cent is eliminated through the bile in humans).
21,27
| Riboflavin pharmacogenomics
The exact cause of migraine headaches is not fully known at present.
The pathophysiology of migraine headache is complex and involves many diverse dysfunctional areas in the brain ranging from a hyperexcitable frontal lobe to hypo-energetic mitochondria which can result in vascular dysfunction, cranial vasodilation and the release of a host of unbalanced neuromodulators including dopamine, norepinephrine and glutamine. 19, 28 A genetic contribution to the aetiology of migraine headache has been suggested by studies which support an estimated 50% hereditability in identical twins. 18 Further evidence comes from observations that at least 50% of patients suffering from migraine headache has a parent who reported similar symptoms 29 and that the risk is higher in people who have relatives affected by it than the general population.
30,31
One of the major genetic disorders that has been linked to migraine headaches is dysfunctional mitochondria. 32 Wang and coworkers proved a link between migraine headaches and cyclic vomiting with variations in gene sequence of mitochondrial DNA (mtDNA).
33
Mitochondria, also known as the power house of the cell, and the nucleus are the only two human cell organelles that possess a distinct DNA called mtDNA and nuclear DNA, respectively. Because of the lack of chromatin protection and a reduced DNA repair system in the mitochondria, the chances of mtDNA mutation are 10-20 times higher than nuclear DNA. As most of the cellular oxygen is utilized by mitochondria (almost 90%), dysfunctional mitochondria can result in the generation of reactive oxygen species which results in oxidative stress to the organelle. 32, 34 The production of free radicals in the mitochondria increases the probability of mtDNA mutation, which can lead to cell death. (See Tables 1, 2 and 3) .
| Riboflavin as a single component to treat adult patients with migraine headache
In 1998, Shoenen and colleagues 40 Secondary outcomes were the number of migraine days, pain severity (as recorded in the patient's diary), duration of headache and days with nausea and vomiting. Using an intention-to-treat analysis, significant differences were found in attack frequency (P<.0001) and number of days (P<.0001). One patient in the riboflavin group developed diarrhoea and one had polyuria; one patient in the placebo group developed abdominal cramps. Five subjects did not complete the study.
Medication adherence was determined by capsule counts. Overall methodology in this study was sound although subject comorbidities
were not described and a longer study period could clarify the lag time seen with riboflavin efficacy. Headache hours and headache intensity did not change significantly.
Rahimdel and co-workers
Three patients experienced diarrhoea, abdominal pain and facial erythema.
Shoenen and co-workers, 43 in an earlier study in 1994, evaluated 49 patients with IHS criteria migraine headache with and without aura.
All patients suffered at least two attacks/month but received no pro- The overall recommendation is graded as strong or weak based on assessment of the balance of benefits and harm. Each drug is also assigned an evidence quality recommendation from high, moderate, low or very low 
| Riboflavin combinations to treat migraine headache
Gaul and colleagues 46 The use of a combination product containing three potentially active ingredients clouds the interpretation of both the efficacy and ADR aspects of this study. While there was a trend towards statistical significance, the study was likely underpowered for the primary endpoint of frequency of migraine headache d/mo. Blinding in the study was possibly compromised by the chromaturia reported in the active treatment group but not in the placebo group.
Maizels and co-workers 48 conducted a Class II trial using a combination product containing riboflavin 400 mg, magnesium 300 mg
(1:1 ratio of magnesium citrate and oxide) and feverfew 100 mg (standardized to 0.7% partheolide). They compared this to a placebo which contained 25 mg riboflavin, in an effort to cause a similar urine colour change in both groups of subjects. These investigators studied 49 adult patients meeting IHS criteria for migraine headache in a randomized, double-blind, placebo-controlled study. The primary outcome was the percentage of patients achieving a 50% or greater reduction in the number of migraine headache attacks during the third month as compared to the run-in month. Secondary outcomes included the number of attacks, severity, use of triptan therapy, migraine headache days and days of tension-type headache. No difference was found between groups in the primary and secondary outcomes. No monitoring for adverse drug events was mentioned in the methodology of the paper or results. In this study, the placebo response rate exceeded that reported in similar trials evaluating prophylactic migraine headache therapy. The placebo response rate for the primary outcome was 44% vs 42% for the combination product. This was a high placebo response rate, much higher than a recent meta-analysis of the placebo response rate in the prophylaxis of migraine headache which was 21%
(95% CI, 13-28%) for the same outcome parameter. 49 This raises several questions such as whether the 25 mg dose of riboflavin in the placebo was exerting a true pharmacologic effect in the study. If, on the other hand, this was a pure placebo effect, why was the response rate so high? Compliance was also not assessed in this study. These questions, along with the lack of adverse drug event monitoring, put the reported data into question.
| Riboflavin as single component to treat children with migraine headache
Two Class I studies 50, 51 suggest that riboflavin, in doses of 50- showing a 50% reduction in migraine headache frequency in patients taking placebo. 49 Due to the fact that the placebo response rate is substantial yet few clinical trials include a placebo, misinterpretation of therapeutic interventions is liable.
| WHAT IS NEW AND CONCLUSION
In addition to a critical evaluation of clinical trial data, questions arise from the available pharmacokinetic and pharmacogenomic data.
Limited information on the absorption of riboflavin suggests that it
involves an active transport mechanism with a maximum of 27 mg absorbed after a single oral dose. 25, 26 Therapeutic doses used in clinical trials are substantially higher than the amount taken as a vitamin supplement. Indeed, riboflavin doses for the prophylaxis of migraine headache range from 50 to 400 mg/d with the most common dose of 400 mg/d (see Table 2 ). If the maximum amount of riboflavin that can be absorbed after a single dose is 27 mg, is there any reason to give more than this as a single dose? Obviously, more studies are needed to clarify this important dosing issue. Another pharmacokinetic area that needs further elucidation is the one hour half-life of riboflavin. 24 With such a short half-life, riboflavin is cleared fairly rapidly from the plasma.
Would more prolonged serum levels increase the efficacy of riboflavin in migraine headache prophylaxis? Could a sustained-released product improve both the bioavailability and prolong the presence of riboflavin in the serum?
Very preliminary evidence 36 suggest that there is perhaps a genetic component to the response to riboflavin treatment in migraine headache. Although limited data are available at present, the possibility that specific populations of patients might be identified that have a high chance of success with riboflavin might clarify its place in therapy.
A significant advantage to using riboflavin in the prophylaxis of migraine headache is its excellent tolerability and low cost. Mild and infrequent gastrointestinal adverse events including vomiting, diarrhoea and upper abdominal pain have been reported. A small number of patients have continuous or more severe gastrointestinal problems which require drug discontinuation. In addition, polyuria and chromaturia have been reported in some studies (see Table 2 ). In fact, orange discoloration of the urine might be considered normative in patients taking high doses of riboflavin. The number needed to harm (NNH)
for riboflavin has been calculated 40 Both drugs decreased the frequency of headache from about 4 episodes/month to about 2.8 along with a reduction in duration and severity; however, no significant differences were found between groups.
Riboflavin side effects were significantly less than propranolol (P=.035) 3 mo Polyuria in 36% (n=18), diarrhoea (n=12), 24%)
Headache frequency was decreased from the 1st month (6.4 episodes/month) to the 2nd month (3.9) to the 3rd month (3.7 per month) and duration decreased (P=0.012 and P=.001, respectively) vs placebo. Disability, as measured by the PedMIDAS, 53 was also decreased (P=.001) 3 mo Significantly fewer adverse effects were reported in the riboflavin group (P-.005)
Frequency of headaches was decreased from 9.2 to 2.4 for riboflavin and 6.5 to 2.1 per month for valproic acid. No statistical difference was found in the frequency, duration or severity of headache between riboflavin and sodium valproate.
limited active absorption of riboflavin, the relatively short plasma half-life and the emerging data on pharmacogenomics. Riboflavin continues to be a promising therapeutic modality in the prevention of migraine headaches; however, additional data are needed to refine its optimal therapeutic position.
